Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Align Technology (ALGN)

NASDAQ: ALGN · Medical Devices · Tempe, AZ

Our rating: Neutral

Call changed from Cautious to Neutral at $159.37, moderate conviction, November 5, 2026.

Breaks if: The Neutral call turns Cautious if two consecutive quarters show year-over-year revenue decline, or if the FCF margin falls below 10% on a trailing basis within the next 12 months (it runs near 12% today). It turns Positive if trailing twelve-month revenue growth reaccelerates to 8% or above within the same 12-month window.

Key figures

Market value$10.9B
Revenue, last 12 months$4.2B
Net income, last 12 months$492M
Free cash flow, last 12 months$603M
Price to earnings22.2×
Free cash flow yield5.5%
Dividend yield0.0%
Operating margin14.9%
Return on equity11.9%
Beta to the S&P 5001.26
Volatility, annualized45.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.0B1.9%$1.90$138M
June 30, 2026$1.1B4.3%$1.51$157M
March 31, 2026$1.0B6.2%$1.57$120M
December 31, 2025$1.0B5.3%$1.88$187M
September 30, 2025$996M1.8%$0.78$169M
June 30, 2025$1.0B−1.6%$1.72$107M
March 31, 2025$979M−1.8%$1.27$27M
December 31, 2024$995M4.0%$1.39$263M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

12 ledger entries and 66 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.